title: Antidepressants and menstruation disorders in women: a cross-sectional study in three centers.
abstract: OBJECTIVE
  The relationship between menstruation disorders and antidepressant drugs usage in women remains unclear. In this study, we aimed to investigate the incidence rate of antidepressant-related menstruation disorders and to examine whether or not antidepressant use is associated with menstrual disorders in women.
  
  
  METHODS
  The study sample was gathered from three centers and four hospitals. A total of 1432 women who met the criteria of inclusion were included in the study. The sample was divided into two groups: the antidepressant group (n=793) and the control group (n=639). The menstruation disorders were established with reports from the study participants on the basis of related gynecological descriptions.
  
  
  RESULTS
  The prevalence of menstrual disorders was significantly higher in the antidepressant group (24.6%) than the control group (12.2%). The incidence of antidepressant-induced menstruation disorder was 14.5%. The antidepressants most associated with menstrual disorders were paroxetine, venlafaxine, sertraline and their combination with mirtazapine. Overall, the incidence rate was similar in women receiving selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors.
  
  
  CONCLUSIONS
  The results of the present study suggest that menstruation disorders are frequently observed in women taking antidepressants and that it appears to be associated with antidepressant use at least in some women.
authors.affiliation: Department of Psychiatry, Meram Faculty of Medicine, Konya University, Konya, Turkey. farukuguz@gmail.com
authors.forename: Faruk
authors.initials: F
authors.lastname: Uguz
authors.forename: Mine
authors.initials: M
authors.lastname: Sahingoz
authors.forename: Seyit Ali
authors.initials: SA
authors.lastname: Kose
authors.forename: Ozgur
authors.initials: O
authors.lastname: Ozbebit
authors.forename: Cem
authors.initials: C
authors.lastname: Sengul
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Selvi
authors.forename: Ceyhan Balci
authors.initials: CB
authors.lastname: Sengul
authors.forename: Medine Gıynas
authors.initials: MG
authors.lastname: Ayhan
authors.forename: Adnan
authors.initials: A
authors.lastname: Dagistanli
authors.forename: Rustem
authors.initials: R
authors.lastname: Askin
mesh_terms: D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D003511:Cyclohexanols / Q000009:adverse effects; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000139:chemically induced* / Q000453:epidemiology; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives; D000078785:Mirtazapine; D017374:Paroxetine / Q000009:adverse effects; D036301:Qualitative Research; D020280:Sertraline / Q000009:adverse effects; D014421:Turkey / Q000453:epidemiology; D000069470:Venlafaxine Hydrochloride; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D003511:Cyclohexanols; D008803:Mianserin; D017374:Paroxetine; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine; D020280:Sertraline